Sarah A.Geers

Sarah Geers represents pharmaceutical and biotechnology clients in intellectual property litigation in a variety of venues, including in district court, arbitration, and at the Patent Trial and Appeal Board (PTAB). Her practice spans Hatch-Waxman and other life science patent infringement actions, inter partes and post-grant review proceedings, and trade secret and misappropriation actions. Her litigation experience spans pre-suit preparation, discovery, trial, and appeal. Sarah is co-leader of Jones Day's PTAB area of focus.

Sarah recently achieved a victory on behalf of Merck in a bench trial of patent infringement actions against 16 generic defendants groups related to Bridion^®, a first-in-class anesthesia reversal agent. She was also part of a team that helped Juno Therapeutics and Sloan Kettering win a more than $1.1 billion final award in a case in which the jury found that defendant Kite Pharma willfully infringed the asserted patent for cancer immunotherapy. Sarah has also been involved in the successful resolution of Hatch-Waxman litigation involving the transdermal patch Butrans^®, as well as a plethora of patent infringement actions involving the pain medication OxyContin^®.

Sarah is currently an adjunct professor at Seton Hall University School of Law, where she teaches a course on patent litigation.

Sarah was named a Law360 "Life Sciences Rising Star" in 2020. In 2023, she was named a "Next Generation Partner" in Patent Litigation by The Legal 500.

Before becoming a lawyer, Sarah worked as a research chemist at Merck & Co., where she was responsible for solid dosage form development and associated preformulation research.